Work

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

Year: 2023

Type: article

Abstract: Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1136/jitc-2022-006361

Authors: Brian I Rini, James Brugarolas, Michael B Atkins

Institutions: Vanderbilt University Medical Center, The University of Texas Southwestern Medical Center, Georgetown University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490